Charles river and navega therapeutics announce comprehensive gene therapy manufacturing collaboration

Wilmington, mass.--(business wire)--charles river laboratories international, inc. (nyse: crl) and navega therapeutics, inc., a biotechnology company developing epigenetic gene therapies, today announced an aav9 production program agreement. as part of charles river's cell and gene therapy (cgt) accelerator program (cap), navega will have access to established contract development and manufacturing (cdmo) capabilities and advisory services to produce an adeno-associated virus (aav)-based gene t.
CRL Ratings Summary
CRL Quant Ranking